Sunovion Pharmaceuticals Inc. Presents Results From a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution

Published: May 20, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced results of a one-year, non-inferiority clinical trial that evaluated BROVANA® (arformoterol tartrate) Inhalation Solution versus placebo for the risk of serious respiratory events (respiratory death or COPD-related hospitalizations due to exacerbations) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The study results, which were presented in three posters at the American Thoracic Society (ATS) International Conference in Philadelphia, showed that of 420 patients treated with BROVANA, 40 experienced at least one serious respiratory event as compared to 63 patients who experienced at least one serious respiratory event of the 421 receiving placebo. Among those patients who experienced an event, the mean time to first event was longer for BROVANA patients (171.7 days) as compared to patients receiving placebo (155 days).

Help employers find you! Check out all the jobs and post your resume.

Back to news